HSP90AA1 and cancer: Thus, there is a continuous need for mechanistic and combination studies in other cancer platforms, including leukemia, which could help in understanding the role of Hsp90 inhibitors in the clinical stage, and to overcome the efficacy and side effects issues [42,43].